Mukund Nadipuram, MD
Hematology & Oncology · Waterloo, IANPI 1962444349
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,234 of the $1,398 with a category attached, or 88.3%. It is spread thinly across 23 manufacturers, the largest accounting for just 13.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $789 and has fallen 92.2% since, to $61 in 2024.
Across 81 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$193
- Johnson & Johnson$178
- Novartis$146
- AstraZeneca$119
- Incyte Corporation$88
- Seagen Inc.$87
- plus $587 from 17 others
Across 3 payments — averaging $34,085 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$92K
- Bristol Myers Squibb$11K
- Pharmacyclics LLC, An Abbvie Company$190
What the payments were for
- Food & beverage$1,23488%
- Education$16412%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 7 | $193 |
| Johnson & Johnson(2 entities) | 18 | $178 |
| Novartis | 9 | $146 |
| AstraZeneca | 7 | $119 |
| Incyte Corporation | 2 | $88 |
| Seagen Inc. | 2 | $87 |
| Eisai Inc. | 3 | $63 |
| Genentech USA, Inc. | 4 | $62 |
| Astellas Pharma US Inc | 4 | $62 |
| Amgen | 3 | $54 |
| Merck | 3 | $53 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Exelixis Inc. | 1 | $34 |
| Tesaro, Inc. | 2 | $28 |
| Pfizer | 2 | $27 |
| Agios Pharmaceuticals, Inc. | 2 | $26 |
| GSK | 2 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $25 |
| Lilly USA, LLC | 2 | $24 |
| Tersera Therapeutics LLC | 1 | $22 |
| Mylan Institutional Inc. | 1 | $20 |
| Sanofi | 1 | $16 |
| Gilead | 1 | $12 |
How this compares
$1,398 in reported general payments places this provider in the 65th percentile of 75 hematology & oncology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 40 | $595,224 |
| KisqaliRibociclib Succinate | 21 | $312,719 |
| TasignaNilotinib Hcl | 13 | $255,012 |
| Lenalidomide | 20 | $249,649 |
| LynparzaOlaparib | 12 | $228,412 |
| InlytaAxitinib | 13 | $198,469 |
| XtandiEnzalutamide | 13 | $170,417 |
| ErleadaApalutamide | 12 | $166,426 |
| Abiraterone Acetate | 42 | $50,617 |
| VenclextaVenetoclax | 12 | $19,133 |
| EliquisApixaban | 22 | $11,981 |
| Anastrozole | 194 | $2,902 |
| Potassium Chloride | 48 | $1,604 |
| Anagrelide Hcl | 17 | $1,137 |
| Exemestane | 13 | $993 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali, Tasigna | $146 | $567,73234 claims |
| AstraZenecaLynparza | $119 | $228,41212 claims |
| PfizerInlyta, Eliquis | $27 | $210,45035 claims |
| Astellas Pharma US IncXtandi | $62 | $170,41713 claims |
| Johnson & JohnsonErleada | $178 | $166,42612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 75 hematology & oncology providers in Iowa.
Other hematology & oncology in Waterloo
- Hussain NaseriWaterloo$2K
- Sakeer HussainCouncil Bluffs$74K
- Usha PerepuIowa City$70K
- Umang SwamiIowa City$54K
- Umar FarooqIowa City$30K
- Brian LinkIowa City$26K
- Mark KarwalIowa City$25K
- Kartik AnandWest Des Moines$24K
- Donald WenderSioux City$22K
- Susannah FriemelDavenport$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.